PT3351539T - Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt - Google Patents

Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt

Info

Publication number
PT3351539T
PT3351539T PT181550799T PT18155079T PT3351539T PT 3351539 T PT3351539 T PT 3351539T PT 181550799 T PT181550799 T PT 181550799T PT 18155079 T PT18155079 T PT 18155079T PT 3351539 T PT3351539 T PT 3351539T
Authority
PT
Portugal
Prior art keywords
glucopyranos
proline
cyclopropyl
cyano
beta
Prior art date
Application number
PT181550799T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PT3351539T publication Critical patent/PT3351539T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PT181550799T 2012-07-26 2013-07-25 Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt PT3351539T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
PT3351539T true PT3351539T (pt) 2023-01-17

Family

ID=48874313

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181550799T PT3351539T (pt) 2012-07-26 2013-07-25 Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt
PT13740309T PT2877460T (pt) 2012-07-26 2013-07-25 COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT13740309T PT2877460T (pt) 2012-07-26 2013-07-25 COMPLEXO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENZIL)-4-(ß-D-GLUCOPIRANOS-1-IL)-BENZENO, MÉTODOS PARA A SUA PREPARAÇÃO E A SUA UTILIZAÇÃO PARA PREPARAR MEDICAMENTOS

Country Status (23)

Country Link
US (1) US9145434B2 (https=)
EP (3) EP4166548A1 (https=)
JP (2) JP6538556B2 (https=)
CN (2) CN104470908A (https=)
AR (1) AR091908A1 (https=)
AU (1) AU2013294947B2 (https=)
BR (1) BR112015001327B1 (https=)
CA (1) CA2878698C (https=)
DK (2) DK3351539T3 (https=)
EA (2) EA025438B1 (https=)
ES (2) ES2937665T3 (https=)
FI (1) FI3351539T3 (https=)
HR (2) HRP20181972T1 (https=)
HU (1) HUE061450T2 (https=)
LT (1) LT3351539T (https=)
MX (1) MX357906B (https=)
PL (2) PL3351539T3 (https=)
PT (2) PT3351539T (https=)
RS (1) RS63881B1 (https=)
SG (1) SG11201500574QA (https=)
SI (2) SI3351539T1 (https=)
TW (1) TW201418275A (https=)
WO (1) WO2014016381A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
ES2969764T3 (es) * 2013-12-17 2024-05-22 Boehringer Ingelheim Vetmedica Gmbh Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
CN115671290A (zh) 2014-01-23 2023-02-03 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
WO2015150299A2 (en) 2014-04-01 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
WO2016046150A1 (en) * 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
HUE052588T2 (hu) * 2014-09-30 2021-05-28 Jiangsu Hengrui Medicine Co Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
KR102659761B1 (ko) 2015-08-27 2024-04-24 베링거잉겔하임베트메디카게엠베하 Sglt-2 억제제를 포함하는 액상 약제학적 조성물
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
KR102226465B1 (ko) 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
US11225500B2 (en) 2017-12-19 2022-01-18 Boehringer Ingelheim Vetmedica Gmbh Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
AU2021222297B2 (en) 2020-02-17 2026-01-22 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び/又は治療のためのsglt-2阻害剤の使用
JP2024527434A (ja) 2021-07-28 2024-07-24 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び/又は治療のためのsglt-2阻害剤の使用
US20240269105A1 (en) 2021-07-28 2024-08-15 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2023277704A1 (en) 2022-05-25 2024-12-05 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
EP4676494A1 (en) 2023-03-06 2026-01-14 Boehringer Ingelheim Vetmedica GmbH Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024223388A1 (en) 2023-04-24 2024-10-31 Boehringer Ingelheim Vetmedica Gmbh Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments
KR20260019532A (ko) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
US20240390317A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254567B2 (en) * 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP2006516257A (ja) * 2003-01-03 2006-06-29 ブリストル−マイヤーズ スクイブ カンパニー C−アリールグルコシドsglt2阻害剤の製造法
CN103030617A (zh) * 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
AU2006289093A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR059489A1 (es) * 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US20080287529A1 (en) * 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN101468976B (zh) * 2007-12-27 2013-11-20 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
CN103910702A (zh) * 2008-08-22 2014-07-09 泰拉科斯有限公司 制备sglt2抑制剂的方法
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos

Also Published As

Publication number Publication date
BR112015001327B1 (pt) 2022-08-16
EA201500038A1 (ru) 2015-07-30
US9145434B2 (en) 2015-09-29
HUE061450T2 (hu) 2023-07-28
HRP20181972T1 (hr) 2019-01-25
EP2877460A1 (en) 2015-06-03
HRP20230081T1 (hr) 2023-03-17
SG11201500574QA (en) 2015-02-27
FI3351539T3 (fi) 2023-02-19
ES2937665T3 (es) 2023-03-30
US20140031540A1 (en) 2014-01-30
DK3351539T3 (da) 2023-01-30
CA2878698C (en) 2021-03-23
EP2877460B1 (en) 2018-09-12
BR112015001327A2 (pt) 2017-07-04
JP2015522644A (ja) 2015-08-06
PL2877460T3 (pl) 2019-04-30
EA201600506A1 (ru) 2017-03-31
AU2013294947A1 (en) 2015-01-22
SI3351539T1 (sl) 2023-03-31
EP3351539A1 (en) 2018-07-25
CA2878698A1 (en) 2014-01-30
TW201418275A (zh) 2014-05-16
RS63881B1 (sr) 2023-02-28
LT3351539T (lt) 2023-02-10
CN104470908A (zh) 2015-03-25
EP4166548A1 (en) 2023-04-19
JP6538556B2 (ja) 2019-07-03
JP2018135384A (ja) 2018-08-30
ES2694675T3 (es) 2018-12-26
AU2013294947B2 (en) 2017-03-30
EP3351539B1 (en) 2022-11-09
PT2877460T (pt) 2018-12-19
WO2014016381A1 (en) 2014-01-30
CN108774200A (zh) 2018-11-09
MX2015000962A (es) 2015-04-16
DK2877460T3 (en) 2019-01-07
PL3351539T3 (pl) 2023-03-06
MX357906B (es) 2018-07-30
SI2877460T1 (sl) 2018-12-31
EA025438B1 (ru) 2016-12-30
AR091908A1 (es) 2015-03-11

Similar Documents

Publication Publication Date Title
PT3351539T (pt) Complexo cristalino de mono-hidrato de 1-ciano-2-(4- ciclopropil-benzil)-4-(beta-d-glucopiranos-1-il)-benzeno e lprolina em água cristalina (1:1:1), métodos para a sua preparação e a sua utilização como um inibidor de sglt
IL231386A (en) Pyrazolequinoline derivatives, their preparation and medical use
EP2669289A4 (en) QUINOLINE-LIKE COMPOUND CONTAINING A PHOSPHORUS-SUBSTITUTED GROUP, PREPARATION METHOD, MEDICAL COMPOSITION CONTAINING THE COMPOUND, AND APPLICATION
SI2590976T1 (sl) Derivati imidazopiridina, postopek njihove priprave in njihova terapevtska uporaba
PH12014500970A1 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
EP2933250A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF
IL233602A0 (en) History of benzamide, their preparation and pharmaceutical preparations containing them
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
PT2870145T (pt) Derivados de indeno, sua preparação e utilização como medicamentos
PL2851075T3 (pl) Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
ZA201407214B (en) Therapeutic preparation and process for preparing said therapeutic preparation
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
SG2014010433A (en) Stable compositions and methods for preparing the same
PL398989A1 (pl) (Z)-6-O-ß-D-4'''-O-metylo-glukopiranozylo-4'-hydroksy-4-metoksy-7-prenyloauron i sposób jego wytwarzania
PL398987A1 (pl) (Z)-6-siarczan-6,4'-dihydroksy-7-prenylo-4-metoksyauronu i sposób jego wytwarzania
GB201112642D0 (en) Surgical hair preparation substance
HK1195303A (en) Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu